Extended Data Fig. 4: Association of PD-L1 protein expression with clinical outcome.
a, Images of PD-L1 staining on tumor cells and immune cells by PD-L1 immunohistochemistry (SP263) (scale bars in each main image and its magnified inset are 90 µm and 20 µm, respectively) are representing. PD-L1 IHC done with the same assay conditions in 180 GO30140 group A and F samples and 199 IMbrave150 tissue samples. b, Prevalence and proportions of PD-L1 staining in either tumor cells (TC) or immune cells (IC). c, Discrete PD-L1 staining at canonical thresholds are tested with a Cox proportional hazards model for association with either overall survival (OS) or progression-free survival (PFS). Points and whiskers in the plot are hazard ratio and confidence interval, respectively. Atezo, atezolizumab; Bev, bevacizumab.
